SCHEDULE 13G: Ronald A. DePinho Discloses 8.3% Stake in TVARDI THERAPEUTICS, INC.
Beneficial Ownership Report
Ronald A. DePinho has filed a Schedule 13G, disclosing beneficial ownership of 8.3% of TVARDI THERAPEUTICS, INC.'s common stock.
Summary
- Ronald A. DePinho reported beneficial ownership of 780,990 shares of TVARDI THERAPEUTICS, INC. common stock.
- This ownership represents 8.3% of the company's outstanding common stock.
- The percentage is calculated based on 9,360,904 shares of common stock outstanding as of May 8, 2025, as reported in the Issuer's Form 10-Q filed on May 13, 2025.
- Mr. DePinho holds sole voting and sole dispositive power over all 780,990 shares.
- The filing indicates that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a strong positive or negative sentiment. It is neutral in tone and content.
Positives
- Disclosure of a significant beneficial ownership stake by an individual may signal confidence in the company's prospects.
- The filing confirms that the shares were not acquired for control-changing purposes, which can reduce uncertainty regarding potential hostile actions.
Negatives
- The document itself does not contain any negative financial or operational information about TVARDI THERAPEUTICS, INC.
Risks
- The document does not explicitly mention specific risks related to TVARDI THERAPEUTICS, INC.'s operations or financial health, as it is an ownership disclosure filing.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Management Comments
- Ronald A. DePinho certified that, to the best of his knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired or held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
This filing is a standard disclosure of significant beneficial ownership by an individual. It does not provide specific insights into broader industry trends or competitive landscape, but it highlights an individual investor's significant stake in a biotechnology company, which is common in the sector given the potential for high growth and specialized knowledge.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: The disclosure of a significant individual shareholder (8.3%) provides transparency regarding the ownership structure and may influence investor perception of the company's stability or future direction.
- Management: Awareness of a substantial individual shareholder may influence management's strategic decisions, although the filing explicitly states the stake is not for control purposes.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 04/15/2025 | Date of event which requires filing of this statement |
| 05/08/2025 | Date as of which 9,360,904 shares of common stock were outstanding, used for percentage calculation |
| 05/13/2025 | Date TVARDI THERAPEUTICS, INC. filed its Quarterly Report on Form 10-Q with the SEC |
| 06/02/2025 | Date the Schedule 13G was signed and filed by Ronald A. DePinho |
Keywords
TVARDI THERAPEUTICS, Ronald A. DePinho, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Biotechnology, Pharmaceuticals, Investment, Shareholder
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.